natgillin/translations-raw huggingface dataset:
the salt is prepared by the addition of an acid in step (ii) selected from the group comprising acetic, tartaric, oxalic, malic, fumaric, hydrochloric and sulphuric acid; and/or 
Postupak prema bilo kojem od zahtjeva 4-7, gdje se sol priprema dodavanjem kiseline u koraku (ii), izabrane iz grupe koja obuhvaća octenu, vinsku, oksalnu, jabučnu, fumarnu, klorovodičnu i sumpornu kiselinu.
"alkynyl" means an aliphatic hydrocarbon group comprising at least one carbon-carbon triple bond and which may be straight or branched and comprising 2 to 15 carbon atoms in the chain; 
"alkinil" znači alifatska ugljikovodična skupina koja sadrži najmanje jednu trostruku vezu ugljik-ugljik i može biti nerazgranata ili razgranata i gadrži 2 do 15 atoma ugljika u lancu;
The Bio Burden is a measure of the level of viable microorganisms present in or on a sample. 
Biološko opterećenje je mjera razine živih mikroorganizama koji su prisutni u/ili na uzorku.
Ecteinascidins have been identified, structurally characterized and synthetic methods for making them have been described. 
Ekteinascidini su identificirani, strukturno okarakterizirani i opisani su sintetički postupci za njihovo pripremanje.
wherein R3 and Y are as defined in formula (I), with a compound of formula (V) 
GV) gdje su R* i Y definirani kao za formulu (I) u patentnom zahtjevu 1, sa spojem formule (V)
represents an optional single bond; 
č-=s predstavlja izbornu jednostruku vezu;
is selected from the group consisting of hydrogen, halo, cyano, (C1-C3) alkyl substituted with from 1 to 5 fluoro groups, and (C1-C3) alkoxy substituted with from 1 to 5 fluoro groups; 
se bira iz skupine koju čine vodik, halogen, cijano, (C1-C3) alkil, supstituiran s 1 do 5 fluornih skupina, te (C1-C3) alkoksi, supstituiran s 1 do 5 fluornih skupina;
The compound according to the above-mentioned [1] or a salt thereof for use in the prophylaxis or treatment of obesity. 
Spoj prema zahtjevu 1 ili njegova sol za uporabu u profilaksi ili liječenju pretilosti.
either ship type mode (1, 2) or shore type mode (3, 4). 
oba na brodski tip rada (1, 2) ili na obalni tip rada (3, 4).
Cytotoxic modular antibody with a molecular weight of up to 60kD, which comprises a CH2 domain and a CH3 domain of a human IgG1 heavy chain and specifically binds to a human receptor of the erbB class with a binding affinity of Kd <10-8 M, wherein the antibody contains a binding site for the receptor of the erbB class within a structural loop region of the CH3 domain of the antibody, and wherein the cytotoxic modular antibody binds to human Fc receptor CD64, FcRn and/or Protein A. 
PATENTNI ZAHTJEVI Citotoksično modularno protutijelo, naznačeno time, da se specifično veže za cilj na površini stanice s afinitetom vezanja od Kd<10-8 M, pri čemu je to Fe (Fcab) koji veže antigen molekule protutijela s funkcijom efektora, koje ima barem jednu od ADCC, ADCP i CD aktivnosti, s mjestom vezanja antigena uređenim na području čvorova od domene CH3 za vezanje na spomenuti cilj na površini stanice, pri čemu cilj na površini stanice je receptor iz razreda erbB.
Composition of Claim 1 for use as a medicament for the treatment of festering wounds, trophic ulcers and burns, infiltrations with marked necrotic and exudative components. 
Sastav prema zahtjevu 1, naznačen time, da služi za uporabu kao lijek za liječenje gnojnih rana, trofičkih čireva i opeklina, infiltracija s naznačenim nekrotičkim i eksudativnim komponentama.
A method for reducing growth lag time of a viral culture comprising, administering to a host cell culture infected with a virus, a composition comprising one or more ethylene oxide propylene oxide (EO-PO) block copolymers, wherein the EO-PO block copolymers comprise poloxamer 407 (Pluronic F127), poloxamer 403 (Pluronic P123) or a combination thereof, wherein the concentration of EO-PO block copolymer is about 0.001 % to about 3.0 % (w/v), and wherein the composition reduces lag time of the viral cultures compared to a control viral culture without administering one or more EO-PO block copolymers. 
Metoda za reduciranje faze prilagodbe kulture virusa sadrži, primjenjujući na stanicu kulture domaćina inficiranu virusom, spoj koji sadrži jedan ili više etilen-oksid-propilen-oksid (EO-PO) blok kopolimera, gdje EO-PO blok kopolimera sadrži poloksamer 407 (pluronski F127), poloksamer 403 (pluronski P123) ili njihovu kombinaciju, gdje je koncentracija EO-PO bloka kopolimera od otprilike 0,001 % do otprilike 3,0 % (m/V) i gdje spoj reducira fazu prilagodbe kultura virusa u usporedbi s kontroliranom kulturom virusa bez primjene jednog ili više EO-PO kopolimera.
administering to a subject in need thereof an amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to Formula I: 
Farmaceutska kompozicija koja sadrži farmaceutski prihvatljiv nosač i farmaceutski učinkovitu količinu soli spoja prema patentnom zahtjevu 1. Farmaceutska kompozicija prema patentnom zahtjevu 2 koja sadrži dodatno terapeutsko sredstvo.
The secondary air flow biasing apparatus of claim 6, wherein the one or more pitch vanes are sized based on a pressure differential within the furnace chamber, between the first elevation and the second elevation. 
Uređaj za upravljanje sekundarnim strujanjem zraka prema zahtjevu 6, naznačen time da su jedna ili više varijabilnih zakretnih lopatica odgovarajućih veličina koje se temelje na razlici tlakova unutar ložišta, između prve visine (D1) i druge visine (D2).
Method according to claim 2, wherein the conversion coating is made by spraying the strip with an aqueous solution of 10 to 160 g/l, preferably 30 to 50 g/l, of a first initial solution comprising 5 to 10 wt.-% hexafluorotitanic acid and 2.5 to 5 wt.-% hexafluorozirconic acid, and 1 to 10 g/l, preferably 7 to 9 g/l, of a second initial solution comprising 20 to 21 wt.-% silica. 
Postupak prema zahtjevu 2, naznačen time, da se konverzijski sloj izvodi putem sprejanja trake s vodenom otopinom od 10 do 160 g/l, poželjno od 30 do 50 g/l prve početne otopine koja sadrži od 5 do 10 masenih % heksafluorotitanske kiseline i od 2,5 do 5 masenih % heksafluorocirkonijske kiseline, te od I do 10 g/l, poželjno od 7 do 9 g/l druge početne otopine koja sadrži od 20 do 21 masenog % silicijevog dioksida.
to produce a first mixture of exo isomers said isomers having a trans-[5,6]-ring junction: 
NO, gdje navedeni izomeri Spoja 17A imaju trans-[5,6]-vezu u prstenu;
An isolated cell that expresses a light chain derived from a hVλ, a hJλ and a mouse Cλ gene, wherein the cell is from, or obtainable from, the mouse of any one of the preceding claims, and wherein the cell comprises: a replacement of one or more heavy chain variable (VH), diversity (DH) and joining (JH) gene segments with one or more human VH, DH, and JH gene segments at an endogenous mouse heavy chain immunoglobulin locus; and 
Izolirana stanica koja izražava antitijelo koje sadrži teški lanac koji sadrži preuređenu humanu sekvencu Vh-Dh-Jh i mišju sekvencu CH i laki lanac koji sadrži preuređenu humanu sekvencu preuređenu humanu sekvencu Vλ-Jλ i mišju sekvencu Ck, naznačena time, što je stanica iz ili se može dobiti iz miša prema bilo kojem od prethodnih patentnih zahtjeva, i naznačena time, što stanica sadrži:
The method of claim 1, wherein mixing a lubricating oil with a first portion of a refrigerant to form a mixture comprises mixing the first portion of the refrigerant in a liquid phase with the lubricating oil downstream of a pump circulating the first portion of the refrigerant. 
Postupak prema Zahtjevu 1, gdje miješanje ulja za podmazivanje s prvom količinom rashladnog sredstva kako bi se oblikovala mješavina podrazumijeva miješanje prve količine rashladnog sredstva u tekućoj fazi s uljem za podmazivanje nizvodno od pumpe koja cirkulira prvu količinu rashladnog sredstva.
As stated, in a preferred embodiment, the material is polyacrylamide and derivatives thereof, most preferably wherein the cross-linked polyacrylamide was prepared from methylene-bis-acrylamide. 
Kao što je navedeno, u ostvarenju kojemu se daje prednost, materijal je poliakrilamid i njegovi derivati, pri čemu je najpoželjnije da je umreženi poliakrilamid pripremljen od metilen-bis-akrilamida.
The method according to one of claims 8 to 12, characterized in that it comprises a fractionating step prior to the refining. 
Postupak prema jednom od zahtjeva 8 do 12, naznačen time što prije rafiniranja sadrži korak frakcioniranja.
all or part of the extracellular portion of an MHC class II B chain; 
cijeli ili dio vanstaničnog dijela a lanca MHC klase II;
A method for preparing a compound of the formula (I): 
Postupak dobivanja spoja formule (I):
Use of a PDE4 inhibitor or a pharmaceutically acceptable salt thereof and a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof for the manufacture of a medicament, in particular the pharmaceutical composition according to the invention, for the preventive or curative treatment of an inflammatory pulmonary disease. 
Uporaba PDEA-inhibitora ili njegove farmaceutski prihvatljive soli i inhibitora reduktaze HMG-CoA ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka, posebno farmaceutskog sastava prema ovom izumu, za preventivno i kurativno liječenje upalne bolesti pluća, pri čemu je PDE4-inhibitor odabran iz
Thus the aggregation status of IL-2 has a clear effect on its in vivo pharmacokinetics. 
Na taj način, stanje agregiranja IL-2 ima jasan učinak na njegove farmakokinetike in vivo.
Compound VI for which LG is Cl) with 2,2-dimethylpiperazine thereby obtaining the compound of formula VII, followed by methylation at the secondary amine. 
Spoja VI kojemu je odlazna skupina C1) s 2,2-dimetilpiperazinom čime se dobiva spoj formule VII, nakon čega slijedi metilacija na sekundarnom aminu.
mapping segments of DNA obtained from the bodily fluid of the pregnant individual to a plurality of polymorphism sequences, wherein the DNA was sequenced under conditions that identify the plurality of polymorphism sequences; 
(a) mapiranje segmenata DNK dobivenih iz tjelesne tekućine trudne osobe na osnovu mnoštva polimorfizama sekvenci, pri čemu je DNK sekvencirana pod uvjetima koji identificiraju mnoštvo polimorfizama sekvenci;
A compound according to the general Formula (Ia) or the general Formula (Ib) the pharmaceutically acceptable acid or base addition salts thereof, the quaternary amines thereof, the stereo chemically isomeric forms thereof, the tautomeric forms thereof and the N -oxide forms thereof, wherein: 
Spoj prema općoj Formuli (Ia) ili općoj Formuli (Ib) [image] [image] njegove farmaceutski prihvatljive kisele ili bazne adicijske soli, njegovi kvaterni amini, njegovi stereokemijski izomerni oblici, njegovi tautomerni oblici i njegovi N-oksidni oblici, naznačen time da:
The process according to claim 1, wherein, during step d), the base used is sodium hydroxide. 
Postupak prema jednom od prethodnih zahtjeva, naznačen time da je korištena baza tijekom koraka d) natrijev karbonat.
The composition of claim 18, wherein the CAR is encoded by a nucleic acid sequence comprising SEQ ID NO:8. 
(v1) CAR je kodiran sekvencom nukleinske kiseline naznačenom u sekvenci SEQ ID NO:8.
The reaction was treated with diethyl ether (100 mL) and stirred for 30 minutes. 
Reakcija je tretirana sa dietil eterom (100 mL) i miješana 30 minuta.
The method according to any one of claims 1 to 4, wherein the coloured or decorative layer comprises one or more epoxy vinyl esters, brominated epoxy vinyl esters, novolac epoxy vinyl ester resins or elastomer modified vinyl ester resins. 
pri čemu sloj podloge sadrži jedan ili više epoksi vinil estera, bromirane epoksi vinil estere, novolak epoksi vinil esterske smole ili elastomerne modificirane vinil esterske smole;
The pneumatic speargun as claimed in claim 1, wherein the return system comprises a pulley (13, 13 I, 13 II, 13 III, 13 IV) at one or both of the head (10) or a body of the speargun. 
Podvodna puška u skladu sa zahtjevom 1, pri čemu sredstvo za vraćanje obuhvaća najmanje jednu remenicu (13, 13', 137, 13", 137) na glavi (10) i /ili na trupu podvodne puške.
Stirring under hydrogen at 3.44 x 105Pa (50 p.s.i.) 
Miješanje pod vodikom na 50 p.s.i.
Direct compression produces a more uniform tablet without granules. 
Ono daje ujednačeniju tabletu bez granula.
The composition for use according to claim 3, wherein the subject has an APOE4/APOE3 genotype. 
Pripravak za uporabu sukladno zahtjevu 3, naznačen time, da ispitanik ima genotip APOE4 / APOE3.
A method according to Embodiment 19 wherein the mutant GPCR contains a plurality of mutations compared to the parent GPCR. 
Metoda u skladu sa Zahtjevom 19 naznačena time da mutacija GPCR-a sadrži više mutacija u usporedbi s izvornim GPCR-om.
More preferably about 30 to about 70 wt % of the total amount of the disintegrant is present in the granules. 
Postupak prema zahtjevu 13, naznačen time da je u granulama prisutno 30-70% ukupne količine sredstva za raspadanje.
The reaction mixture was stirred at 50 °C over night. 
Reakcijska smjesa se na 50 "C preko noći.
The above embodiments relates to the compounds of the invention having formula I 
Gornji oblici se odnose na spojeve s formulom I
The anti-TNFa antibody, for use according to any one of claims 1-9, wherein the subject is selected from the group consisting of a subject having an AN count of greater than or equal to 3 at baseline, a subject who is a female, a subject who is over 40 years old, a subject who is a smoker, and any combination thereof. 
Anti-TNFa protutijelo za uporabu prema bilo kojem od zahtjeva 1-9, naznačeno time, da se subjekt bira iz skupine koja se sastoji od subjekta koji ima početni broj AN veći ili jednak 3, subjekta koji je ženska osoba, subjekta koji je stariji od 40 godina, subjekta koji je pušač, 1li bilo koje od njihovih kombinacija.
R<14> is hydrogen, substituted or unsubstituted C1-C4 linear alkyl, C6 or C10 substituted or unsubstituted aryl, C1-C9 substituted or unsubstituted heterocyclic, C1-C11 substituted or unsubstituted heteroaryl; c) 
R'* je vodik, supstituirani ili nesupstituirani C,-C, nerazgranati alkil, C, ili C,, supstituirani ili nesupstituirani aril, Ci-Co supstituirani ili nesupstituirani heterocikl, C;-C;, supstituirani ili nesupstituirani heteroaril;
A space unit according to claim 2, characterized in that the backrest portion (5a) can be folded into a bed on top of the seat portion (5b). 
Prostorna jedinica sukladno zahtjevu 2, naznačena time, da se dio naslona (5a) može sklopiti u krevet na vrh sjedećeg dijela (5b).
The roll of any of the preceding claims, wherein the Cr content in the steel composition is between 7.0 - 11 % Cr in terms of % per weight of total roll weight. 
Valjak prema prethodnim zahtjevima, pri čemu sadržaj Cr u sastavu čelika iznosi između 7,0-11 % Cr u postotnoj težini ukupne težine valjka.
The monolithic intravaginal ring of claim 7, wherein the progesterone is released from the intravaginal ring at 10 mg/day to 40 mg/day in vivo, or wherein the progesterone is released from the intravaginal ring at 10 mg/day to 30 mg/day in vivo, or wherein the progesterone is released from the intravaginal ring at 15 mg/day to 25 mg/day in vivo. 
Monolitni intravaginalni prsten u skladu s patentnim zahtjevom 7, naznačen time, da se iz intravaginalnog prstena otpušta od 10 mg/dan do 40 mg/dan progesterona in vivo, ili pri čemu se iz intravaginalnog prstena otpušta od 10 mg/dan do 30 mg/dan progesterona in vivo ili pri čemu se iz intravaginalnog prstena otpušta od 15 mg/dan do 25 mg/dan progesterona in vivo.
Ar2 is tetrazolyl, triazolyl, imidazolyl, pyrazolyl, pyrrolyl, or dioxothiazinyl, and is substituted with 0-2 substituents selected from the group consisting of amino, oxo, halo, cyano, and C1-6alkyl; and 
Area Ar' je tetrazolil, triazolil, imidazolil, pirazolil, pirolil ili dioksotiazinil, i supstituiran je sa 0-2 supstituenta izabrana iz grupe koju čine amino, okso, halo, cijano i Cig alkil; i
A mixed-halide perovskite according to paragraph 58 or paragraph 63 wherein X is iodide and X' is fluoride or chloride, or X is fluoride and X' is chloride, bromide or iodide. 
Miješani halid perovskit u skladu s patentnim zahtjevom 16 ili 17, naznačen time, da je X jodid, a X' je fluorid ili klorid, ili je X fluorid, a X' je klorid, bromid ili jodid.
The antibody or antibody fragment of at least one of the preceding claims, wherein the treated cancer differentially expresses C1ORF32 and wherein the treatment comprises administering to the patient an effective amount of the antibody or antibody fragment. The antibody or antibody fragment of at least one of the preceding claims, wherein said antibody or antibody fragment is conjugated to a cytotoxin selected from the group consisting of taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin and analogs or homologs thereof, antimetabolites, alkylating agents, anthracyclines, antibiotics, anti-mitotic agents, duocarmycins, calicheamicins, maytansines and auristatins. 
Protutijelo ili fragment protutijela prema zahtjevu 1 za uporabu u terapiji ili protutijelo ili fragment protutijela prema zahtjevu 2 za uporabu za liječenje raka, naznačeno time što je navedeno protutijelo ili fragment protutijela konjugirano na terapeutski dio odabran od citotoksina, lijeka ili radiotoksina, pri čemu je citotoksin odabran iz skupine koja sadrži taksol, citokalasin B, gramicidin D, etidij bromid, emetin, mitomicin, etopozid, tenopozid, vinkristin, vinblastin, kolhicin, doksorubicin, daunorubicin, dihidroksi antracin dion, mitoksantron, mitramicin, aktinomicin D, 1-dehidrotestosteron, glukokortikoide, prokain, tetrakain, lidokain, propranolol, puromicin i njegove analoge ili homologe, antimetabolite, alkilirajuća sredstva, antracikline, antibiotike, anti-mitotička sredstva, duokarmicine, kalikeamicine, maitanzine i auristatine.
Another embodiment is directed to compounds of Formula (Ib): 
36. Spoj formule (Ib) e R 2 RA
a compound wherein Y is thiazol-2-yl, Z is 6-trifluoromethyl-benzothien-2-yl, s is 2, and R1 is cis-3,5-dimethyl; or a pharmaceutically acceptable salt form thereof. 
spoj u kome je Y oksazol-5-il, Z je 1-(4-fluorofenil)-indol-5-il, i s je 0; ili solvat ili farmaceutski prihvatljiv oblik njegove soli.
Valve connector for medical lines for infusion by means of a fluid introducer, comprising: a tubular body having an inlet end designed for the engagement of the introducer, and an outlet end, 
- < cjevasto tijelo (1) koje ima ulazni kraj ulazni kraj (4) konstruiran za angažiranje uvodnika (S), i izlaznog kraja (10),
The compound of claim 19, wherein X4, is NR42 and X42 is N. 
Spoj prema zahtjevu 19, pri čemu je X4 je NR42 i X42 je N.
component (B) is acetamiprid, wherein the weight ratio of component (A) to component (B) is from 125:1 to 1:33. 
komponenta (B) je acetamiprid, pri čemu maseni odnos komponente (A) prema komponenti (B) iznosi 125:1 do 1:33.
As it can be observed in table 13, all the compound tested have a potent in vivo anti-thrombotic activity. 
80 12 Kako se može vidjeti u tablici 13, svi ispitani spojevi imaju jako in vivo antitrombozno djelovanje.
characterized in that said single filler has one median particle size, said median particle size being greater than about 3.2 microns, and being in the wrapper in an amount less than about 16% by weight; and 
omotač koji opkoljava stupac duhana za pušenje, pri čemu omotač: sadrži celulozna vlakna i punilo, a punilo ima srednju veličinu čestica veću od oko 3,2 mikrona; i
the filtering step (ii) comprises filtering the aqueous pharmaceutical solution through a first filter, or a first filter and a second filter, and wherein the aqueous pharmaceutical solution is passed through the second filter at a rate of 3-25 liters/hour; preferably at a rate of 3-22 liters/hour; more preferably at a rate of 3-15 liters/hour; or more preferably at a rate of 3-10 liters/hour; 
stupanj filtriranja (ii) sadrži filtriranje vodene farmaceutske otopine kroz prvi filter, ili prvi filter i drugi filter, i kod čega se vodena farmaceutska otopina propušta kroz drugi filter pri brzini od 3-25 litara na sat; pri brzini od 3-22 litre na sat; pri brzini od 3-15 litara na sat; ili pri brzini od 3-10 litara na sat;
Note that the geometrical form is not limited to the shown step and other forms are viable as long as they procure a resilient or at least deformable nature of the sealing member. 
Treba napomenuti da geometrijski oblik nije ograničen na prikazanu stepenicu i drugi oblici su mogući sve dok oni osiguravaju elastično svojstvo ili barem svojstvo da se može deformirati element za nepropusno zatvaranje, kao što je to definirano u patentnim zahtjevima.
The compound as claimed in claim 1, wherein the substituents on aryl groups are independently selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, cyano, thioalkyl, cycloalkyl groups; and/or wherein the substituents on heteroaryl or heteroaromatic groups are selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, aryl, aralkyl, cyano, alkylthio, thioalkyl groups; and/or wherein the substituents on heterocyclyl groups are selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, aryl, aralkyl, cyano, alkylthio, thioalkyl groups. 
Spoj prema zahtjevu 1, naznačen time, da su supstituenti na aril-skupinama neovisno odabrani od sljedećih skupina: vodik, halogen, alkil, alkoksi, hidroksil, haloalkil, haloafkoksi, cijano, tioalkil, cikloalkil; i/ili time, da su supstituenti na heteroaril-skupinama 1li heteroaromatskim skupinama odabrani od sljedećih skupina: vodik, halogen, alkil, alkoksi, hidroksil, haloalkil, haloalkoksi, ari!, aralkil, cijano, alkiltio, tioalkil; i/ili time, da su supstituenti na heterociklil-skupinama odabrani od sljedećih skupina: vodik, halogen, alkil, alkoksi, hidroksil, haloalkil, haloalkoksi, aril, aralkil, cijano, alkiltio, tioalkil.
One or several binders according to the invention are preferably selected from the group consisting of polyvidone (used synonymously for povidone), methylcellulose, hydroxypropylmethylcellulose (HPMC), hydroxymethylcellulose, starch, gelatin, and the like. 
Kruti pripravak prema zahtjevu 1 ili 2, naznačen time, da je vezivo odabrano iz skupine koju čine polividon/povidon, metilceluloza, hidroksipropilmetilceluloza (HPMC), hidroksimetilceluloza, škrob i želatina.
The pharmaceutical composition according to claim 1, further comprising at least one additional peptide containing an amino acid sequence selected from the group consisting of SEQ ID NO 9 to SEQ ID NO 12, or containing a variant amino acid sequence that is at least 80 % identical to that of SEQ ID NO 9 to SEQ ID NO 12, or polynucleotide containing a nucleic acid encoding SEQ ID NO 9 to SEQ ID NO 12 or the variant amino acid sequence. 
15. Peptid u skladu s bilo kojim patentnim zahtjevom od 1 do 4 za uporabu u skladu s patentnim zahtjevom 13 ili 14, pri čemu se navedeno cjepivo nadalje sastoji od najmanje jednog dodatnog peptida odabranog iz SEQ ID br. 1 do SEQ ID br. 9, i SEQ ID br. 11 do SEQ ID br. 26.
The compound of claim 19, wherein said compound is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-isopropyl-indol-4-yl)-5-hydroxy-[1,2,4]triazole, or a tautomer, pharmaceutically acceptable salt, solvate, or clathrate thereof. 
Spoj prema zahtjevu 19, pri čemu navedeni spoj je 3-(2,4-dihidroksi-5-izopropil-fenil)-4-(1-izopropil-indol-4-11)-5hidroksi-[1,2,4]-triazol ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat.